GSK’s Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK’s own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen.
The post GSK Gets FDA Approval for New Severe Asthma Drug With a Dosing Advantage appeared first on MedCity News.
